Summary & Overview
HCPCS J7329: Hyaluronan (Trivisc) Intra-articular Injection, 1 mg
HCPCS Level II code J7329 identifies a hyaluronan derivative product (Trivisc) intended for intra-articular injection at a unit size of 1 mg. Nationally, injectable hyaluronans are significant in musculoskeletal care for patients with joint degeneration seeking non-surgical symptom management. This code documents the specific drug product and unit for billing and utilization tracking.
Key payers included in the analysis are Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find a concise national perspective on how J7329 is classified for claims, the clinical context for its use in intra-articular procedures, and what elements typically appear in coverage and billing scenarios.
The publication provides benchmarks and policy-relevant context, including common service settings, expected documentation elements for intra-articular administration, and payer-aligned considerations affecting coverage and claims processing. It also highlights where input data is not available, such as payer-specific reimbursement rates or linked ICD-10 codes, directing readers to seek payer policy documents for rate and coverage determinations.
Billing Code Overview
HCPCS Level II code J7329 describes hyaluronan or derivative, trivisc, for intra-articular injection, 1 mg. This code denotes a single-dose pharmacologic product formulated for intra-articular administration to joints, commonly used in procedures aimed at joint lubrication and symptomatic relief of degenerative joint conditions.
Service Type: Intra-articular injection of hyaluronan derivative
Typical Site of Service: Outpatient clinic, physician office, or ambulatory surgical center
Data not available in the input for associated taxonomies, ICD-10 diagnoses, related codes, and service line.
Clinical & Coding Specifications
Clinical Context
A typical patient is a 58-year-old ambulatory adult with symptomatic osteoarthritis of the knee presenting to an orthopedic clinic after conservative measures (physical therapy, oral NSAIDs, weight loss, and activity modification) provided insufficient pain relief. The clinician confirms focal tibiofemoral joint pain with exam and radiographs consistent with moderate osteoarthritis. After shared decision-making, the clinician schedules an intra-articular viscosupplementation injection using J7329 (Hyaluronan or derivative, TriVisc, 1 mg). On the day of service the patient registers at an outpatient ambulatory surgical center or office-based procedure suite. Vital signs and an allergy check are performed; informed consent specific to intra-articular hyaluronan injection is obtained and documented. The procedural workflow includes aseptic skin preparation, optional local anesthetic, ultrasound or landmark-guided intra-articular needle placement, aspiration if effusion present, and administration of the J7329 product. Post-procedure monitoring for 10–30 minutes evaluates immediate adverse reactions. Documentation includes indication, laterality (LT or RT modifier when applicable), product name and NDC or lot number, dose, number of injections, procedural details, and post-procedure instructions. Typical sites of service are the outpatient office, ambulatory surgical center, or hospital outpatient department. Common payors covering this service include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, BUCA, and Medicare.
Coding Specifications
| Modifier | Description |
|---|